CHILDRENS CANCER GROUP

儿童癌症组

• 批准号: 2007160
• 负责人: PHILIP P BREITFELD
• 金额: $ 21.59万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 1994
• 资助国家: 美国
• 起止时间: 1994-03-11 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2007160
• 关键词: Wilms' tumor; bone marrow transplantation; bone neoplasms; brain neoplasms; child (0-11); clinical trials; combination cancer therapy; combination chemotherapy; cooperative study; cytogenetics; cytokine; germ cell neoplasms; hepatoblastoma; human subject; human therapy evaluation; leukemia; longitudinal human study; neoplasm /cancer chemotherapy; neoplasm /cancer epidemiology; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neuroblastoma; pediatric neoplasm /cancer; therapy compliance

This is a proposal for the continued support of Indiana University's participation in Children's Cancer Group (CCG) activities. The Indiana University program has been a funded member of CCG since 1971. It serves as an important resource for study subjects as it ranks 4th in study entries (245) and 4th in total patients in active follow-up in CCG (1070) for the 12 month period ending 7/31/92. Study participation has been broad including therapeutic (first line, second line, new agents) as well as non-therapeutic studies (epidemiologic, biologic). Importantly, study participation has increase by 68% since 1989 at the Indiana University program. Members of the Indiana University program serve on 4 strategy groups (Wilm's, ANLL, Neuroblastoma, Brain Tumor) and serve as chairman of 2 other scientific committees in CCG (Local Tumor Control, Cytogenetics) demonstrating a significant contribution to the scientific activities. Participation and contributions to CCG activities by the Indiana University program will continue to grow. The Section of Pediatric Hematology/Oncology at Indiana University has added 8 new faculty members since July, 1991. Seven of 12 faculty have one or more NIH grants and one is a Howard Hughes Medical Institute Associate Investigator. Six of these new faculty have or will assume leadership roles in study and scientific committees in CCG. New areas of interest represented by these faculty include neuro-oncology, late effects of cancer therapy, acute non- lymphoblastic leukemia, neuroblastoma, germ cell tumors, cytokines and cancer biology. This compliments our current CCG activities in the areas of cytogenetics, tumor imaging, acute lymphoblastic leukemia, and Wilms' tumor. In regard to patient entry on study, it is anticipated that the Indiana University program will place up to 260 patients/year on CCG studies during the project period. Finally, Indiana University personnel are dedicated to protocol compliance and high quality data management in order to ensure the highest quality clinical science.

这是印第安纳大学继续支持的提案 参与儿童癌症小组 (CCG) 活动。印第安纳州 大学项目自1971年以来一直是CCG的资助成员。它服务于 作为学习科目的重要资源，在学习中排名第四 CCG 中主动随访患者总数排名第 4（245 名）和第 4 名（1070 名） 截至 92 年 7 月 31 日的 12 个月期间。研究参与广泛 包括治疗药物（一线、二线、新药）以及 非治疗性研究（流行病学、生物学）。重要的是，学习 自 1989 年以来，印第安纳大学的参与度增加了 68% 程序。印第安纳大学项目成员服务于 4 个战略 小组（Wilm's、ANLL、神经母细胞瘤、脑肿瘤）并担任主席 CCG 的其他 2 个科学委员会（局部肿瘤控制、细胞遗传学） 证明对科学活动的重大贡献。 印第安纳州对 CCG 活动的参与和贡献 大学课程将继续增长。儿科科 印第安纳大学血液学/肿瘤学新增 8 名教职人员 自 1991 年 7 月以来。12 名教师中有 7 名获得一项或多项 NIH 资助，一名 是霍华德休斯医学研究所的副研究员。其中六个 新教师已经或将在研究和科学方面发挥领导作用 CCG 的委员会。这些教师代表的新兴趣领域 包括神经肿瘤学、癌症治疗的迟发效应、急性非 淋巴细胞白血病、神经母细胞瘤、生殖细胞肿瘤、细胞因子和 癌症生物学。这对我们当前在这些领域的 CCG 活动表示赞赏 细胞遗传学、肿瘤成像、急性淋巴细胞白血病和维尔姆斯氏病 瘤。关于患者参加研究，预计 印第安纳大学项目每年将安排多达 260 名患者接受 CCG 项目期间的学习。最后，印第安纳大学人员 致力于协议合规性和高质量数据管理 以确保最高质量的临床科学。